Cordlife GroupCLIFF 33 FCF Margin % is -15.76% as of Mar. 2026. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 55.39% on this metric.
The historical rank and industry rank for Cordlife Group's FCF Margin % or its related term are showing as below:
CLIFF'
s FCF Margin % Range Over the Past 10 Years
Min: -53.21 Med: 6.79 Max: 24.62
Current: -4.73
During the past 13 years, the highest FCF Margin % of Cordlife Group was 24.62%. The lowest was -53.21%. And the median was 6.79%.
CLIFF's FCF Margin % is ranked worse than 55.39% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs CLIFF: -4.73
Cordlife Group FCF Margin % Related Terms
Cordlife Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cordlife Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cordlife Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a FCF Margin % of -15.76% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #113 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 55.4%.
Is Cordlife Group's FCF Margin % too high?
Cordlife Group's current FCF Margin % is -15.76%. Based on the distribution chart, Cordlife Group ranks #113 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #113 out of 204 companies for FCF Margin %. This places Cordlife Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cordlife Group and its competitors. Cordlife Group's current FCF Margin % is -15.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current FCF Margin % is -15.76%. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current FCF Margin % is -15.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
FCF Margin %: -15.76%
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
